Cel-Sci Corp | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Cel-Sci Corp is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for CEL-SCI Corporation in Multikine Phase 3 Data Published in Peer-Reviewed Scientific Journal Pathology and Oncology Research (Phase 3).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| CEL-SCI Corporation | Multikine Phase 3 Data Published in Peer-Reviewed Scientific Journal Pathology and Oncology Research | n/a | Phase 3 | Public pipeline row |
| ASCO 2022 | n/a | n/a | Phase 3 | Public pipeline row |
| Hypothermia | Spinal Cord Injury, Acute | n/a | Na | Public pipeline row |
| Cold environment participants with spinal cord injury | Spinal Cord Injuries | Paraplegia | n/a | Na | Public pipeline row |
| LI | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Soft Palate | n/a | Phase 3 | Public pipeline row |
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT01265849 | Phase 3 | COMPLETED | 928 | 2020-05-15 |
| NCT04215939 | Na | COMPLETED | 16 | 2020-07-25 |
| NCT02991690 | Na | RECRUITING | 120 | 2026-08 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.